You are here

An epitope-focused nanoparticle vaccine for anthrax

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44AI142939-01A1
Agency Tracking Number: R44AI142939
Amount: $300,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA18-574
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-05-01
Award End Date (Contract End Date): 2020-04-30
Small Business Information
3030 BUNKER HILL ST STE 350
San Diego, CA 92109-5757
United States
DUNS: 160242579
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DAVID WHITACRE
 (858) 242-1524
 dwhitacre@vlp-biotech.com
Business Contact
 DAVID WHITACRE
Phone: (858) 242-1524
Email: dwhitacre@vlp-biotech.com
Research Institution
N/A
Abstract

Abstract We have successfully developed a highly immunogenicoptimized and lyophilizable epitope focusedbivalent anthrax vaccinereferred to as LND LF VLPusing our novel proprietary platform technology which incorporates the vaccine target sequence into highly immunogenic virus like particlesThis new vaccine targets two distinct neutralizing determinantswhich are not targeted by Biothraxthe currently approved vaccine for anthraxWhen formulated with human use adjuvantsthis new vaccine has potential to elicit very rapid protective immunity with only one or two injectionsOur proposal will focus on two overarching aimsto demonstrate the efficacy of two immunizations with the LND LF VLP in human use adjuvants for protection of rabbits from high dose aerosol spore challenge with Bacillus anthracis Ames strain andto optimize and develop standard operating procedures for the expressionpurification and quality assurance of the LND LFVLP vaccine in a manner enabling eventual scale up production by a contract manufacturing organizationThis new epitope focusedVLP vaccine promises to be a highly stablesafe and strategic new vaccine for anthrax Spores of Banthracisthe causative agent of anthraxcan be weaponized and represent a threat to our armed forces and civilians at largeWe are developing a new highly potent vaccine for anthrax that will be a valuable addition to the immunopreventatives in the Strategic National stockpile

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government